6/3/2019 | DD | Orexigen Therapeutics amended liquidation plan effective as of May 31
|
5/31/2019 | DD | Orexigen Therapeutics records $31,000 loss from operations for April
|
5/17/2019 | DD | Orexigen Therapeutics amended plan of liquidation confirmed by court
|
4/30/2019 | DD | Orexigen Therapeutics posts $708,000 loss from operations for March
|
4/2/2019 | DD | Orexigen Therapeutics posts $1.45 million operating loss for February
|
3/27/2019 | DD | Orexigen wins interim OK of disclosure statement; plan hearing May 17
|
3/7/2019 | DD | Orexigen Therapeutics files plan of liquidation, disclosure statement
|
3/4/2019 | DD | Orexigen Therapeutics posts $1.45 million operating loss for January
|
1/30/2019 | DD | Orexigen Therapeutics posts $175,000 December operating loss, no sales
|
12/14/2018 | DD | Orexigen Therapeutics posts $239,000 November operating loss
|
12/3/2018 | DD | Orexigen Therapeutics posts $79,000 October operating loss, no sales
|
11/27/2018 | DD | Orexigen agreement party, subsidiary appeal fund entitlement ruling
|
11/13/2018 | DD | Court rules Orexigen agreement party not entitled to disputed funds
|
10/31/2018 | DD | Orexigen Therapeutics posts $526,000 September loss from operations
|
10/1/2018 | DD | Orexigen Therapeutics records $81,000 loss from operations for August
|
8/30/2018 | DD | Orexigen Therapeutics records $2.08 million operating loss for July
|
7/31/2018 | DD | Orexigen completes $73.5 million sale; directors and officers resign
|
7/30/2018 | DD | Orexigen Therapeutics records $1.72 million operating loss for June
|
7/13/2018 | DD | Orexigen granted exclusivity extension to negotiate and confirm plan
|
7/3/2018 | DD | Orexigen Therapeutics marks $3.97 million operating loss for May
|
6/28/2018 | DD | Orexigen Therapeutics $75 million sale of assets approved by court
|
6/27/2018 | DD | Orexigen seeks exclusivity extension to negotiate and confirm plan
|
6/22/2018 | DD | Orexigen cancels auction, to seek approval of $75 million asset sale
|
5/30/2018 | DD | Orexigen Therapeutics marks $7.21 million April loss from operations
|
5/18/2018 | DD | Orexigen $3.67 million McKesson receivable settlement OK’d by court
|
5/11/2018 | DD | Orexigen to get $3.67 million under McKesson receivable settlement
|
5/4/2018 | DD | Orexigen marks $1.33 million operating loss for March 12 to March 31
|
4/23/2018 | DD | Orexigen asset sale procedures OK’d; $75 million lead bid received
|
4/13/2018 | DD | Orexigen gets final approval of $70.35 million DIP financing package
|
4/3/2018 | DD | Orexigen Therapeutics announces Nasdaq decides to delist company stock
|
3/28/2018 | DD | Orexigen Therapeutics official unsecured creditors committee appointed
|
3/16/2018 | BKCVDDEMHY | Prospect News reports five new defaults for week of March 8-March 14
|
3/13/2018 | DD | Orexigen wins interim approval to access to $15 million of financing
|
3/12/2018 | CV | Market Commentary: Guidewire, Etsy continue to dominate the convertibles space; Deutsche Bank seen as cheap
|
3/12/2018 | CVDD | Orexigen files for Chapter 11, plans to hold auction for assets
|
12/1/2017 | CVLM | Orexigen to exchange $6.46 million of convertibles for new stock
|
12/30/2016 | CVLM | Orexigen buys back $35 million of 2.75% convertibles due 2020 at 28.25
|
12/21/2016 | CV | Market Commentary: Sucampo prices upsized deal, trades over par; trader speculates Orexigen being repurchased
|
12/20/2016 | CVLM | Orexigen amends 0% convertibles to allow for 2.75% convertible buyback
|
10/20/2016 | CV | Market Commentary: Convertibles see positive tone; DISH bonds expand on swap; Citrix bonds add; Peabody gains
|
3/15/2016 | PP | Orexigen Therapeutics to sell $165 million convertible notes, warrants
|
9/10/2015 | PP | Orexigen raises $60 million through private placement of common stock
|
5/12/2015 | PP | Market Commentary: Planned SunEdison seen cheap; existing SunEdisons finish unchanged; Depomed drops outright
|
5/12/2015 | CV | Market Commentary: Planned SunEdison seen cheap; existing SunEdisons finish unchanged; Depomed drops outright
|
12/6/2013 | CV | Orexigen Therapeutics greenshoe lifts convertible sale to $115 million
|
12/3/2013 | CV | New Issue: Orexigen sells $100 million seven-year convertibles at 2.75%, up 32.5%
|
12/3/2013 | CV | Market Commentary: New Orexigen trends toward par; planned RPM deal in focus; GT Advanced, Endologix on tap
|
12/3/2013 | CV | Market Commentary: Midday Commentary: Orexigen lifts at open, but shares weaken slightly; Alliant Tech eyed
|
12/2/2013 | CV | Market Commentary: Midday Commentary: Cobalt International tanks; Orexigen plans $100 million convertible
|
12/2/2013 | CV | Orexigen to sell $100 million seven-year convertibles to yield 2.75%-3.25%, up 27.5%-32.5%
|
12/2/2013 | CV | Market Commentary: Cobalt drops outright, contracts on hedge; Frontline trades at 69.5; Orexigen on tap
|
10/25/2012 | PP | Orexigen Therapeutics prices $60.5 million public sale of stock
|
10/24/2012 | PP | Orexigen Therapeutics to price public offering of common shares
|
9/14/2012 | CVHYPF | Orexigen Therapeutics files $150 million shelf covering debt, stock
|
12/15/2011 | PP | Orexigen Therapeutics prices $90 million public sale of equity units
|
12/14/2011 | PP | Orexigen Therapeutics to price public offering of common-share units
|
12/3/2009 | SS | Orexigen Therapeutics investor buys 650,000 shares for 7.5% interest
|
9/4/2009 | CVHY | Orexigen Therapeutics files $150 million shelf covering debt, stock
|
8/20/2009 | SS | Orexigen Therapeutics investor boosts ownership to 7.6% with purchase
|
5/6/2009 | CVHY | Orexigen Therapeutics files $75 million shelf covering debt, stock
|